ACRIVON THERAPEUTICS INC (ACRV)

US0048901096 - Common Stock

7.26  -0.03 (-0.41%)

Fundamental Rating

3

ACRV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. ACRV has a great financial health rating, but its profitability evaluates not so good. ACRV is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

In the past year ACRV has reported negative net income.
In the past year ACRV has reported a negative cash flow from operations.

1.2 Ratios

ACRV has a Return On Assets of -29.93%. This is in the better half of the industry: ACRV outperforms 68.85% of its industry peers.
The Return On Equity of ACRV (-31.94%) is better than 78.58% of its industry peers.
Industry RankSector Rank
ROA -29.93%
ROE -31.94%
ROIC N/A
ROA(3y)-25.37%
ROA(5y)N/A
ROE(3y)-28.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ACRV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ACRV has been increased compared to 1 year ago.
There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ACRV has an Altman-Z score of 8.20. This indicates that ACRV is financially healthy and has little risk of bankruptcy at the moment.
ACRV has a better Altman-Z score (8.20) than 83.19% of its industry peers.
There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.2
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 16.16 indicates that ACRV has no problem at all paying its short term obligations.
With an excellent Current ratio value of 16.16, ACRV belongs to the best of the industry, outperforming 90.44% of the companies in the same industry.
A Quick Ratio of 16.16 indicates that ACRV has no problem at all paying its short term obligations.
ACRV has a better Quick ratio (16.16) than 90.44% of its industry peers.
Industry RankSector Rank
Current Ratio 16.16
Quick Ratio 16.16

0

3. Growth

3.1 Past

ACRV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.56%.
EPS 1Y (TTM)-34.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -2.31% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.07%
EPS Next 2Y-0.39%
EPS Next 3Y2.92%
EPS Next 5Y-2.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

ACRV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACRV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.39%
EPS Next 3Y2.92%

0

5. Dividend

5.1 Amount

ACRV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (10/14/2024, 8:11:44 PM)

7.26

-0.03 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap224.84M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.93%
ROE -31.94%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 16.16
Quick Ratio 16.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-34.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y9.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y